Professional development Vacancies

Bioequivalence under new requirements: State Expert Center specialists took part in the BioBridges conference 2026 in Prague

01.10.2026 738 views

Specialists of the Department for Assessment of Bioavailability and Equivalence took part in the international BioBridges 2026 conference, which was held on 24-25 September in Prague at the Institute of Pharmacology of Charles University.

BioBridges is an international non-profit platform for professional dialogue between representatives of regulatory authorities, the scientific community and the pharmaceutical industry. Its participants discuss the latest scientific and regulatory approaches to bioequivalence, medicinal product development, including hybrids and biosimilars, as well as modern research methods.

The focus of this year's conference:

  • current changes to international ICH standards;
  • modern approaches to conducting and assessing bioequivalence studies;
  • modelling of pharmacokinetic processes;
  • changes in approaches to assessing the similarity of biological medicinal products;
  • methods for studying products for topical use, including ophthalmic and intranasal forms.

Separate sessions were dedicated to new approaches to assessing complex dosage forms and the use of in vitro methods in regulatory practice.

For the Center's specialists, participation in BioBridges 2026 became an opportunity to discuss with international experts the practical application of new regulatory approaches, compare the experience of different countries, and update the knowledge needed for the expert evaluation of bioequivalence and equivalence materials.

The experience gained will be used in the Center's further work when assessing registration dossier materials, improving expert approaches, and harmonizing them with current international recommendations. This is of particular importance for the assessment of generic medicinal products, complex dosage forms, and new methodological approaches, where requirements and scientific approaches are constantly updated.

For patients, such expert work means, above all, a substantiated assessment of whether a medicinal product ensures proper efficacy, safety, quality, and the expected effect in accordance with current scientific and regulatory requirements. The development of competencies in the field of bioequivalence also contributes to the emergence of quality generic medicinal products on the market and to expanding access to treatment.

Participation in international professional platforms such as BioBridges gives the Center the opportunity to remain in the context of changes in European and international regulatory practice and to use modern scientific approaches in its daily expert work.